SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors..

圣地亚哥--（商业新闻短讯）--Arcturus Therapeutics Holdings Inc.（以下简称“公司”，“Arcturus”，纳斯达克：ARCT），一家全球信使RNA药物公司，专注于开发传染病疫苗和药物，以治疗肝脏和呼吸道罕见疾病中未满足的医疗需求，今天宣布任命新的独立董事Moncef Slaoui博士为公司董事会成员。。

“Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and commercialization of several therapeutics and vaccines,” said Joseph Payne, President & Chief Executive Officer of Arcturus. “We warmly welcome Moncef to the Board of Directors and look forward to working with him as we advance our pipeline of next generation mRNA medicines.”.

Arcturus总裁兼首席执行官约瑟夫·佩恩（JosephPayne）表示：“蒙塞夫·斯劳伊（MoncefSlaoui）博士在医药产品创新、几种疗法和疫苗的开发和商业化方面拥有非凡的战略专业知识。“我们热烈欢迎Moncef加入董事会，并期待着在我们推进下一代mRNA药物管道的过程中与他合作。”。

“I am delighted to join the Board of Arcturus Therapeutics as we embark on this exciting phase of growth,” said Dr. Moncef Slaoui. “I look forward to helping advance the Arcturus pipeline of mRNA vaccines and therapeutics utilizing the next-generation STARR® self-amplifying mRNA and LUNAR® delivery technology platforms.”.

Moncef Slaoui博士说：“我很高兴加入Arcturus Therapeutics董事会，因为我们正在进入这一令人兴奋的增长阶段。”。“我期待着利用下一代STARR®自我扩增mRNA和LUNAR®传递技术平台，帮助推进大角星mRNA疫苗和治疗剂的生产线。”。

Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc.

蒙塞夫·斯劳伊博士最近是“扭曲速度行动”的首席科学顾问。在他的领导下，该行动在描述病毒基因序列后不到11个月的时间内实现了有史以来最快的多种新型冠状病毒疫苗的开发，制造和批准。斯劳伊博士曾在多家生物技术公司董事会任职，其中包括Moderna公司。

and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company..

和Lonza Group AG，他担任Galvani和疫苗开发平台公司Vaxcyte的董事会主席。。

Dr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a restructuring to improve focus on innovation and productivity.

Slaoui博士在葛兰素史克（GSK）任职近30年，担任领导职务，包括葛兰素史克股份有限公司董事会成员；制药研发董事长；全球研发、疫苗和肿瘤学主席；全球疫苗董事长。作为制药研发主席，斯劳伊博士领导了一次重组，以提高对创新和生产力的关注。

As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease..

作为全球疫苗公司的主席，Slaoui博士直接参与了葛兰素史克公司的疫苗生产线，从而创造了14种新疫苗，包括Shingrix®，用于预防带状疱疹；Cervarix®，预防宫颈癌；Mosquirix，预防疟疾；Rotarix®，预防轮状病毒胃肠炎；和Synflorix，以预防肺炎球菌疾病。。

In 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world, served on the Advisory Committee to the Director of the NIH from 2011 to 2016, and has advised the U.S. President's Council of Advisors on Science and Technology..

2016年，Slaoui博士因其在发展中国家常见的未充分研究的疾病方面的工作而被公认为《财富》杂志（Fortune）50位最伟大的世界领袖之一，2011年至2016年担任美国国立卫生研究院（NIH）主任咨询委员会成员，并为美国总统科学技术顾问委员会（U.s.President's Advisors on Science and Technology）提供咨询。。

Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, and was a Professor of Immunology at the University of Mons, Belgium. He received an accelerated Master of Business Administration from IMD, Switzerland in 1998..

Slaoui博士拥有布鲁塞尔自由大学分子生物学和免疫学博士学位，在哈佛医学院和塔夫茨大学医学院完成博士后研究，并曾任比利时蒙斯大学免疫学教授。1998年，他从瑞士IMD获得了工商管理硕士学位。。

About Arcturus Therapeutics

关于大角星治疗学

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise.

Arcturus Therapeutics Holdings Inc.（纳斯达克股票代码：ARCT）成立于2013年，总部位于加利福尼亚州圣地亚哥，是一家全球mRNA药物和疫苗公司，拥有以下技术：（i）LUNAR®脂质介导的递送，（ii）STARR®mRNA技术（sa mRNA）和（iii）mRNA药物以及药品制造专业知识。

Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

大角星开发了世界上第一种自我扩增信使RNA（sa mRNA）新型冠状病毒疫苗（Kostaive®），并获得批准。Arcturus正在与CSL-Seqirus进行创新mRNA疫苗的全球合作，并在日本成立了一家合资企业ARCALIS，专注于mRNA疫苗和治疗剂的生产。

Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Arcturus的管道包括可能治疗鸟氨酸转氨甲酰酶缺乏症和囊性纤维化的RNA治疗候选物，以及针对SARS-CoV-2（COVID-19）和流感的合作mRNA疫苗计划。大角星的多功能RNA治疗平台可应用于多种类型的核酸药物，包括信使RNA，小干扰RNA，环状RNA，反义RNA，自扩增RNA，DNA和基因编辑疗法。

Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn..

大角星的技术涵盖了其广泛的专利组合（在美国、欧洲、日本、中国和其他国家拥有400多项专利和专利申请）。有关更多信息，请访问www.ArcturusRx.com。此外，请通过Twitter和LinkedIn与我们联系。。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success and continued advancement of the Company’s pipeline and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), and the impact of general business and economic conditions.

本新闻稿包含前瞻性声明，涉及1995年《私人证券诉讼改革法案》提供的安全港的重大风险和不确定性。除本新闻稿中包含的历史事实声明外，任何声明均为前瞻性声明，包括有关战略、未来运营、公司管道和合作计划（包括与CSL-Sequirus合作的新型冠状病毒和流感计划）的成功可能性和持续发展的前瞻性声明，以及一般商业和经济状况的影响。

Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading 'Risk Factors' in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov.

大角星可能无法实际实现上述任何前瞻性声明中披露的计划、意图或期望或预测，您不应过度依赖此类前瞻性声明。这些声明仅是当前的预测或预期，并受到已知和未知的风险、不确定性和其他因素的影响，这些因素可能导致我们或我们行业的实际业绩、活动水平、绩效或成就与前瞻性声明所预期的大不相同，包括Arcturus最新年度报告（表10-K）中“风险因素”标题下讨论的内容，以及随后向美国证券交易委员会提交的文件或提交给美国证券交易委员会的文件，这些文件可在美国证券交易委员会网站www.SEC.gov上查阅。

Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise..

除非法律另有要求，大角星不打算或有义务更新或修订任何前瞻性声明，这些声明仅在其发布之日起发表，无论是由于新信息、未来事件或情况或其他原因。。

Trademark Acknowledgements

商标确认

The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR® and STARR®, are the property of Arcturus. All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

本公告中出现的大角星徽标和其他大角星商标（包括LUNAR®和STARR®）均为大角星的财产。本公告中的所有其他商标、服务标志和商号均为其各自所有者的财产。